STAT

Shaped like a tennis ball, this cancer protein was thought ‘undruggable.’ Amgen found a way to target it

What sets Amgen's small molecule pill apart, even among genetically driven cancer drugs, is the elusiveness of its target: mutant KRAS with structure like a tennis ball.
The KRAS oncogene's structure has been compared to a tennis ball. Source: Michael Dodge/Getty Images

Scientists have long known that a mutant form of the cell-signaling protein called KRAS causes cancer, but discovering drugs capable of blocking KRAS has proven difficult. The protein is spherical and nearly featureless — its structure has been compared to a tennis ball —  leaving potential drugs with few, if any, effective attachment points.

On Wednesday, () is reporting early but potential progress in an effort to block mutant

You're reading a preview, sign up to read more.

More from STAT

STAT4 min read
Opinion: As The Need For Organ Transplants Grows, The Number Of Transplant Physicians Dwindles
Medical training has been long been characterized as a "grand bargain" in which trainees make personal sacrifices with the expectation of a better life later. But that's a deal many…
STAT2 min read
Alexion Acquiring Achillion To Expand Reach Into Rare, Immune-related Disease
Alexion Pharmaceuticals said that it will acquire Achillion Pharmaceuticals to expand its pipeline of experimental drugs targeting rare diseases of the immune system.
STAT9 min read
The ‘Unbelievable Journey’ Of CRISPR, Now On Netflix
"Unnatural Selection," a four-part docuseries debuting today, dissects the stories, science, and ethics behind genome editing.